Buy Aceon | Cheap Aceon | Buy Aceon Online
Buy Aceon | Cheap Aceon | Buy Aceon Online
FAQ
Search
Memberlist
Usergroups
Galleries
Register
Profile
Log in to check your private messages
Log in
Buy Aceon | Cheap Aceon | Buy Aceon Online Forum Index
->
Buy Aceon | Cheap Aceon | Buy Aceon Online
Post a reply
Username
Subject
Message body
Emoticons
View more Emoticons
Font colour:
Default
Dark Red
Red
Orange
Brown
Yellow
Green
Olive
Cyan
Blue
Dark Blue
Indigo
Violet
White
Black
Font size:
Tiny
Small
Normal
Large
Huge
Close Tags
Options
HTML is
OFF
BBCode
is
ON
Smilies are
ON
Disable BBCode in this post
Disable Smilies in this post
Confirmation code: *
All times are GMT + 2 Hours
Jump to:
Select a forum
Jakaś kategoria
----------------
Buy Aceon | Cheap Aceon | Buy Aceon Online
Topic review
Author
Message
cheapbag214s
Posted: Sat 18:17, 23 Nov 2013
Post subject: could not tolerate it or were unwilling to use it
Sofosbuvir results in a higher cure rate for two hepatitis C subtypes ,[url=http://www.omgfund.com/]michael kors factory outlet[/url]
AMSTERDAM, Netherlands, April 25 () -- Extended use of the drug sofosbuvir resulted in a high cure rate in two subtypes of hepatitis C that account for 25 percent of U.S. cases, researchers say.Lead investigator Dr. Ira Jacobson of Weill Cornell Medical College said 207 patients enrolled in the clinical trial of sofosbuvir,[url=http://www.homactus.com]Beats By Dre Cheap[/url], known as POSITRON, because they either did not respond to interferon, could not tolerate it or were unwilling to use it, even though no other treatment options were available to them."The new sofosbuvir therapy offers a much-needed alternative to standard therapy with interferon, which can cause significant side effects for hepatitis C patients," Jacobson said in a statement. "We have dreamed for years of being able to eliminate interferon from our hepatitis C regimens and this study is one of several that are finally bringing us very close to realizing that goal."The study, published in The New England Journal of Medicine, found for genotype 2, 12 weeks of treatment resulted in response rates of 86 percent, compared to 94 percent for 16 weeks of treatment. For genotype 3, the response rates were 30 percent for 12 weeks and 62 percent for 16 weeks."This new treatment represents a paradigm shift in the way that hepatitis C is going to be treated," Jacobson said. Jacobson estimated as many as half of patients with hepatitis C infection either can't use interferon or don't want to use it because of side effects.The journal publication coincides with a presentation of the findings at the International Liver Congress in Amsterdam, the Netherlands.
fora.pl
- załóż własne forum dyskusyjne za darmo
Powered by
phpBB
© 2001, 2005 phpBB Group
Regulamin